title: Small molecule alpha(v) integrin antagonists: novel anticancer agents.
abstract: The members of the integrin family are targets that potentially provide both therapeutic and diagnostic opportunities. Advances in the understanding of the signalling pathways, transcriptional regulation and the structure/function relationships of the adhesion molecules to extracellular matrix proteins have all contributed to these opportunities. The role of the integrins in pathological processes in both acute and chronic diseases, include ocular, cancer (solid tumours and metastasis), cardiovascular (stroke and heart failure) and inflammatory (rheumatoid arthritis) conditions. Various therapeutic candidates, including antibodies, cyclic peptides and peptidomimetics, have been identified. This review will focus on the key role of the alpha(v) integrin (alpha(v)beta(3) and alpha(v)beta(5)) in angiogenic processes in tumours, including its potential use in cancer diagnostics and therapy.
authors.affiliation: General Pharmacology, DuPont Pharmaceuticals Co., Route 141 and Henry Clay Road, PO Box 80400, Wilmington, DE 19880-0400, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Kerr
authors.forename: A M
authors.initials: AM
authors.lastname: Slee
authors.forename: S A
authors.initials: SA
authors.lastname: Mousa
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors*; D008024:Ligands; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016023:Integrins; D008024:Ligands; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5